Diagnosis of Anderson-Fabry's disease in over seventy-year-old women: Description of two cases

Aging Clinical and Experimental Research

Volumn 18, Issue 4, 2006, Pages 340-343

  Buechner, Susanne ^a   Luzzi, Chiara ^a   Mannucci, Marco ^a   Massi, Daniela ^a   Borsini, Walter ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Anderson Fabry's disease; Cardiomyopathy; Geriatric age; Leukoencephalopathy

Indexed keywords

ALPHA GALACTOSIDASE; AMIODARONE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; GLYCOSPHINGOLIPID; PROPAFENONE;

ACUTE HEART INFARCTION; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; AORTA VALVE REGURGITATION; ARTICLE; AUTOPSY; BRAIN ANGIOGRAPHY; BRAIN INFARCTION; BRAIN RADIOGRAPHY; CARDIOMYOPATHY; CASE REPORT; CEREBELLUM HEMORRHAGE; CLINICAL FEATURE; COLON ADENOCARCINOMA; DAILY LIFE ACTIVITY; DIFFERENTIAL DIAGNOSIS; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; ENDARTERECTOMY; FABRY DISEASE; FATALITY; FEMALE; FEMORAL ARTERY; GENE DELETION; HEART ATRIUM FIBRILLATION; HEART DILATATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; LEUKOCYTE; LEUKOENCEPHALOPATHY; LIPID STORAGE; LUNG DISEASE; MENTAL DISEASE; MITRAL VALVE REGURGITATION; PARESTHESIA; THROMBOEMBOLISM;

EID: 33751114940     PISSN: 15940667     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03324669     Document Type: Article

References (10)

1. Roland D, Hilbert P, Dehout F, Pirson Y, Van Maldergem L. Fabry disease in Belgium: ascertainment of 12 families. Acta Paediatr 2002; 439 (Suppl): 115-20.
2. Desnick RJ, Ioavannou YA. Alpha-galactosidase A deficiency: Fabry disease. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular basis of inherited disease. New York: Mc Graw-Hill, 1995: 2741-84.
3. Mac Dermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38: 769-75.
4. Borsini W, Giuliacci G, Torricelli F, Pelo E, Martinelli F, Scordo MR. Anderson-Fabry disease with cerebrovascular complications in two Italian families. Neurol Sci 2002; 23: 49-53.
5. Chimenti C, Ricci R, Pieroni M, Natalke L, Russo MA, Frustaci A. Cardiac variant of Fabry's disease mimicking hypertrophic cardiomyopathy. Cardiologia 1999; 44: 469-73.
6. Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophyic cardiomyopathy. Circulation 2004; 110: 1047-53.
7. Eng CM, Guffon N, Wilcox WR, et al. International Collaborative Fabry Disease Study group. Safety and Efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9-16.
8. Schiffmann R, Kopp JB, Austin HA, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285: 2743-9.
9. Spinelli L, Pisani A, Sabbatini M, et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Gent 2004; 66: 158-65.
10. Avner P, Heard E. X-chromosome inactivaction: counting, choice and initiation. Nature Rev Genet 2001; 2: 59-67.